ArticleHeliyon2023

Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report.

Ruiqi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.